|Home | About | Journals | Submit | Contact Us | Français|
Language: | French
Chronic hepatitis B (CHB) is a dynamic disease that is influenced by host and virological factors. The management of CHB has become more complex with the increasing use of long-term oral nucleos/tide analogue antiviral therapies and the availability of novel diagnostic assays. Furthermore, there is often a lack of robust data to guide optimal management such as the selection of therapy, duration of treatment, potential antiviral side effects and the treatment of special populations. In November 2011, the Canadian Liver Foundation and the Canadian Association for the Study of the Liver convened a consensus conference to review the literature and analyze published data, including other international expert guidelines on CHB management. The proceedings of the consensus conference are summarized and provide updated clinical practice guidelines to assist Canadian health care providers in the prevention, diagnosis, assessment and treatment of CHB.
L’hépatite B chronique (HBC) est une maladie dynamique influencée par l’hôte et les facteurs virologiques. La prise en charge de l’HBC s’est compliquée avec l’utilisation accrue des analogues de nucléosides et de nucléotides antiviraux sur une longue période et la disponibilité de méthodes diagnostiques novatrices. De plus, on manque souvent de données solides pour orienter une prise en charge optimale, telle que la sélection de la thérapie, la durée du traitement, les effets secondaires potentiels des antiviraux et le traitement des populations particulières. En novembre 2011, la Fondation canadienne du foie et l’Association canadienne pour l’étude du foie ont organisé une conférence consensuelle pour procéder à une analyse de la bibliographie et des données publiées, y compris d’autres lignes directrices internationales d’experts sur la prise en charge de l’HBC. Les débats de la conférence consensuelle sont résumés et donnent lieu à une mise à jour des lignes directrices cliniques pour aider les dispensateurs de soins canadiens à prévenir, diagnostiquer, évaluer et traiter l’HBC.
Chronic hepatitis B infection remains a major public health burden in Canada. Since the 2007 Canadian Association for the Study of the Liver (CASL) update in the management of chronic hepatitis B virus (HBV) (1), our knowledge of the natural history of chronic hepatitis B, the assessment of infected patients and the treatment of the virus have improved. In November 2011, the CASL and the Canadian Liver Foundation organized the consensus conference to develop a new hepatitis B guideline to assist clinicians and health care providers in providing health services and treatment to chronic hepatitis B patients.
The consensus committee addressed the following questions:
The present report presents the proceeding of the consensus development conference and the update will focus on answering the above questions.
The process used to arrive at consensus was as follows: An Organizing Committee was appointed by the CASL and the Canadian Liver Foundation. This committee invited expert speakers to review the current literature on different topics. After the presentation, questions from the audience were addressed. A Writing Committee, selected by the Organizing Committee, assessed the information from the presentations and from other sources, and prepared a document that was circulated to the speakers for comment. The strength of the recommendations and the evidence supporting the recommendations have been evaluated and graded according to the grading system adapted from the American College of Cardiology and the American Heart Association Practice Guidelines and the Grading of Recommendations Assessment Development and Evaluation (GRADE) system (2–8) (Table 1). The report presents the recommendations representing the best medical practice in the assessment and the management of chronic hepatitis B infection.
Hepatitis B is one of the most common infections in the world, with more than 360 million chronic carriers (9). In Canada, chronic hepatitis B infection is primarily a disease of immigrants from endemic countries. In a childhood HBV surveillance study, the non-Canadian-born children had an RR 12 times higher than that of Canadian-born children (10). There had been attempts to estimate the number of hepatitis B carriers in Canada. Statistics Canada estimated the number of HBV-infected individuals to be approximately 600,000 and this was based on the assumption of a 6% rate in immigrants, a 1% rate in Canadian-born individuals and a 4% rate in Aboriginals (11). In a recent review of available data (12), the estimated overall prevalence of HBV carriers in the general population in Canada is approximately 2% and the high-risk groups include immigrants, Aboriginals and street-connected individuals (12). Because immigrants and street-connected individuals tend to live in large urban centres, the seroprevalence rate is not uniformly distributed across the country.
Chronic hepatitis B can progress to end-stage liver disease and there is also a significant risk of hepatocellular carcinoma (HCC) development. After decades of infection, the rate of cirrhosis or chronic liver failure is 20% to 25%, and the rate of HCC development is approximately 5% (13,14). In a recent Ontario Burden of Infectious Disease Study (15), hepatitis B was the fourth-ranked pathogen causing significant years of life lost due to premature mortality.
Chronic HBV infection is often asymptomatic and diagnosed late unless at-risk individuals are screened for the infection. Symptoms indicate a late stage of infection and complications may have already developed. When these complications of chronic liver failure or HCC develop, they are more difficult to reverse and are often fatal. Chronic hepatitis B infection will remain a public health problem and major health resource utilization in Canada over the next several decades.
The ideal hepatitis B vaccination policy should provide immune protection against hepatitis B infection in infancy when the risk of chronic infection is highest and in adolescence when acute infection relating to the risk behaviours of intravenous drug use and unprotected sex can potentially occur.
The Canadian provinces of Alberta, Saskatchewan, Manitoba, Ontario, Quebec, Nova Scotia, and Newfoundland and Labrador offer universal vaccination of adolescents or preadolescents rather than universal neonatal vaccination. These provinces also use maternal screening to identify at-risk babies who should be vaccinated. This policy approach addresses the mother-to-infant transmission of the virus. However, it does not address that hepatitis B infection can be transmitted horizontally during childhood. In Canada, hepatitis B is a disease of immigrants and usually more than one family member are affected. The mother might not have the infection; however, another family member or sibling can have the infection and can transmit the virus to a child through unrecognized close contact with infectious body fluids. Although the virus is found mainly in the blood and serous fluids of an infected person, it can also be present in the saliva at concentrations 1000 to 10,000 times less than in blood. Population studies have documented that a significant portion of chronic hepatitis B infection was acquired during infancy or early childhood (16,17). The immunization strategy of providing adolescent vaccinations without offering neonatal vaccinations will miss the opportunity to prevent chronic infection in infants or young children when chronic infection can occur in 90% of infants and 25% to 50% of young children.
Successive Canadian consensus conferences on the management of chronic viral hepatitis have recommended neonatal hepatitis B vaccination (1). In 2001, British Columbia became the first province offering universal hepatitis B vaccination to infants and ‘catch-up’ adolescent vaccination. Since the implementation of this vaccination policy, the reported incidence of acute HBV infection in British Columbia continues to decline and the province has an annual incidence consistently below the national average (18). Currently, 171 of the 193 WHO members have implemented the policy of universal hepatitis B vaccination of infants (19). There is no reason that the 13 health care jurisdictions in Canada should not have a harmonized policy similar to the WHO.
The hepatitis B surface antibody (anti-HBs) titre decreases over time. After 10 years, more than one-third of children vaccinated during infancy will have anti-HBs titres below the accepted protective antibody level of 10 IU/L (20–22). However, most hepatitis B-vaccinated adults can mount a protective immune response even 18 years after receiving a primary series of infancy vaccinations. In groups at high risk of HBV infection, a low rate of infection is observed 18 years after vaccination (23,24). Routine booster vaccination is not indicated in average-risk populations. For healthy adults who fail to respond to the first series of vaccines, additional doses of vaccine can stimulate the immune system, producing a protective antibody level in 50% to 70% of these adults.
At-risk adults who have negative hepatitis B surface antigen (HBsAg) and anti-HBs tests should receive hepatitis B vaccination (Table 2). Hepatitis B vaccination is also recommended for patients who have chronic liver disease other than hepatitis B even though the efficacy of vaccinating this population is not as pronounced (25–27). These patients with liver disease may not be able to sustain a second injury to the liver, and having immunity against HBV may be beneficial. The Advisory Committee on Immunization Practices from the Centers for Disease Control and Prevention (Georgia, USA) also recommends all hepatitis B-unvaccinated diabetic adults 19 to 59 years of age be vaccinated against the virus (28).
Chronic hepatitis B infection is often asymptomatic for decades and screening is important in identifying infected individuals for transmission counselling, disease progression monitoring and treatment to prevent end-stage liver disease or untreatable HCC. In Canada, the majority of infants, children and adolescents have received the hepatitis B vaccine, and the risk of chronic infection is very low. The risk groups include immigrants, Aboriginals and individuals who have potential risk factors for viral hepatitis or HIV infection (Table 3). These groups should be screened for chronic hepatitis B infection with HBsAg, anti-HBs and hepatitis B core antibody (anti-HBc). If the HBsAg test is positive, the person should be fully assessed for chronic viral hepatitis and HIV infection. If the person is positive for anti-HBc only, a booster HBV vaccine should be given to assess for anamnestic immune response (29). If the booster vaccine cannot elicit an anti-HBs response, the person may have occult infection and the person can experience activation of hepatitis B during immunosuppression (30).
Chronic hepatitis B infection has a complex natural history and is a dynamic disease that can change over time. It has been estimated that 25% of the carriers will develop significant chronic liver disease or HCC.
The natural history of HBV infection can progress through five phases (Table 4). Patients may not go through every phase and the duration of each phase is highly variable in each patient. In mother-to-infant, perinatal or childhood infection, an immune tolerant phase is normal and may last 10 years to more than 20 years. During the immune-tolerant phase, the patients do not have active hepatitis. Alanine aminotransferase (ALT) levels are persistently low and HBV DNA levels are very high. The liver biopsy shows no or minimal inflammation. In clinical practice, biopsies are seldom performed to diagnose this phase and clinicians rely on a persistently low ALT levels to make the diagnosis. This practice is not completely reliable because inflammation can occur in the setting of high-normal ALT, and intermittent ALT testing may miss short-lived periods of elevated ALT levels. A normal transient elastography study will be useful to confirm that the patients are indeed in the immune-tolerant phase.
The immune clearance phase can last less than five years to more than 25 years. ALT levels are elevated and HBV DNA level decreases. During this phase, the patients can develop cirrhosis, or seroconversion from hepatitis B e antigen (HBeAg)-positive to hepatitis B e antibody (anti-HBe)-positive. The predictors of seroconversion are high ALT, low HBV DNA, patient age younger than 40 years and absence of cirrhosis (31–33). After the immune-clearance phase, the infection may become inactive or may evolve into HBeAg-negative chronic hepatitis after a quiescent phase. For the patients who are permanently in an inactive phase, ALT levels are normal and the HBV DNA level is low or nondetectable. These patients tend to have a good prognosis. Patients who have established cirrhosis before HBeAg seroconversion continue to have a high risk of HCC.
Patients who experience reactivation of the virus after HBeAg seroconversion can develop HBeAg-negative chronic hepatitis. These patients tend to have fluctuating ALT and HBV DNA levels. A yearly single finding of normal ALT and HBV DNA <2000 IU/mL does not prove that the patients are still in the inactive carrier state. These HBeAg-negative chronic hepatitis patients are at risk of developing end-stage liver disease and HCC. This means that patients who have inactive disease for years must continue to undergo regular follow-up for the detection of reactivation. Spontaneous resolution of the infection with clearance of HBsAg occurs in only 0.5% to 0.8% of chronic carriers per year (34,35).
The risks for cirrhosis and HCC development correlate with the severity of chronic inflammation or fibrosis, HBV DNA level, duration of infection, male sex and concomitant liver diseases such as alcoholic liver disease. The rate of progression to end-stage liver disease or HCC occurs at a rate of 5% to 10% per year, with an annual death rate of 20% to 50% after the development of complications (36–38).
There are special laboratory tests that are crucial or helpful tools in the evaluation of chronic hepatitis B patients and in the guidance of treatment decisions. This section discusses these tests.
HBV DNA viral load testing is a crucial tool to monitor and manage chronic hepatitis B patients. HBV DNA level is a predictor of cirrhosis and HCC development (39–44). The HBV DNA International Unit (IU/mL) has been adopted to improve comparability among commercial assays (44). These assays have good dynamic range to enable accurate determination of the viral DNA levels in patients. HBV DNA measurements will usually need to be repeated at intervals of three to six months to monitor disease evolution. During treatment of the infection, HBV DNA measurements are frequently needed to monitor treatment response and noncompliance, and assess for treatment-resistant mutant development. Therefore, there should be no restriction on the frequency of HBV DNA viral load testing.
Transient elastography is a noninvasive ultrasound test measuring liver stiffness (LS). Health Canada approved the use of transient elastography to determine liver fibrosis in 2009. The LS measurement is a good predictor of fibrosis and is an alternative to liver biopsy in determining liver fibrosis (45). The test is quick and easy to perform. With proper training, it is also operator independent. Because it is noninvasive, it is an ideal test to monitor fibrosis progression in chronic hepatitis B patients; changes in LS could be a reflection of liver disease progression. There is an approximately 5% test failure rate and these failures are commonly related to obesity and narrow intercostal spaces in small individuals. Using a cut-off of 7.1 KPa, transient elastography has a very high negative predictive value (>90%) in predicting significant fibrosis or cirrhosis. Compared with the aspartate aminotransferase (AST)/platelet ratio index and the FIB-4 test, transient elastography is better in predicting significant fibrosis and cirrhosis (46).
In chronic hepatitis B patients, intermittent, severe flares of hepatitis can occur. During these flares, the LS values can increase significantly and the stiffness value changes may not imply progression of fibrosis if the testing is performed during flares (47,48). The overall trend is more important than a single measurement. It is possible to use an algorithm of LS measurement to guide the selection of patients for treatment (46,49).
Other noninvasive, serum-based tests for detection of hepatic fibrosis (eg, Fibrotest, FibroSpect II, AST/platelet ratio index, Forns fibrosis index, FIB-4) can be used in the assessment of chronic hepatitis B infection. However, there is less information available to guide the use of these tests in chronic hepatitis B patients.
Liver biopsy is often performed in diagnosing liver disease, assessing severity or prognosis, and guiding management of patients with liver diseases. It is the current reference standard. The majority of liver biopsies are obtained by a clinical examination-guided transcutaneous, transthoracic approach or an ultrasound-guided subcostal approach. The transvenous or transjugular approach is occasionally used in patients with significant risk of hemorrhage. Pain is the most common complication of transcutaneous liver biopsy and can occur in up to 85% of cases (50). The pain is usually mild to moderate and can be treated with small doses of narcotics. The most significant complication of liver biopsy is intraperitoneal hemorrhage, which, when severe, can be fatal (51,52). Severe postliver biopsy hemorrhage has been estimated to occur in between one in 2500 to one in 10,000 biopsies. Mortality after liver biopsy is rare and is usually related to severe hemorrhage. Complications such as pneumothorax, hemothorax and gallbladder puncture are less likely to occur with ultrasound-guided liver biopsy.
To justify the risk of the liver biopsy procedure, the information from the histological assessment of the liver will be important in guiding the management of the patient. It is possible that patients can have more than one liver condition. Liver biopsy is important in this setting. In cases of discrepancy between noninvasive fibrosis testing and clinical impression, liver biopsy will also be useful.
Biopsy sampling error can occur, especially if the biopsy size is inadequate and has fewer than 11 evaluable portal tracts (53,54). The biopsy result should be interpreted in conjunction with clinical, laboratory and imaging assessment.
Serum HBsAg concentration reflects the number of hepatitis B covalently closed circular genomes (cccDNA), the transcriptional activity of cccDNA and the host immune response against the virus. Not too surprisingly, HBsAg level varies across HBV genotypes and during different phases of infection (55). The HBsAg level is higher during the immune tolerant phase compared with the immune clearance phase. The HBsAg level tends to be lower in patients with inactive infection. Currently there are two commercial assays, the Architect QT assay (Abbott Laboratories, USA) and the Elecsys HBsAg II Quant assay (Roche Diagnostics, Switzerland). There is a good correlation between the HBsAg quantification by these two assays (56,57).
In the recent literature, HBsAg concentration monitoring has been shown to be helpful in the management and in guiding treatment of chronic hepatitis B infection. In inactive HBV carriers, the HBsAg level tends to be significantly lower than that of patients with chronic hepatitis, and a low level of HBsAg is also a predictor of HBsAg seroclearance (58–60).
HBsAg monitoring may have a role in pegylated interferon (PEG IFN) treatment of chronic hepatitis B. In patients who received PEG IFN treatment for HBeAg-positive chronic hepatitis, early decline of HBsAg level was associated with HBeAg seroconversion and sustained response post-treatment (61). At week 12 of PEG IFN treatment, a lack of HBsAg level decline was a predictor of poor IFN treatment response (61). For HBeAg-positive patients who do not experience a decline in HBV DNA and HBsAg levels during week 12 of PEG IFN treatment, the likelihood of response will be small and treatment discontinuation can be considered. In patients who received PEG IFN treatment for HBeAg-negative chronic hepatitis, HBsAg level decline at weeks 12 to 24 and end of treatment level were also predictors of response (61,62).
The HBV genome is heterogeneous and can be grouped into eight recognized genotypes (A through H) based on the criterion of 8% or more differences in DNA sequence variations in the HBV genome. HBV genotypes have a characteristic geographical distribution, with genotype A being common in Europe, North America and Africa, genotypes B and C in the Far East, genotype D being found worldwide, genotype E in Africa, genotype F in South America and Alaska, genotype G in North America and genotype H in Central America (63–65). HBV genotype population studies have suggested there are differences in the natural history and clinical outcomes among different HBV genotypes. In the Far East, genotype B has been associated with less severe liver disease, lower rates of HBeAg reactivity and higher spontaneous HBeAg seroconversion than genotype C (66). Genotype C is associated with more frequent HCC development. Less information is available for genotypes A and D. Genotype A seems to have milder disease and cause less cirrhosis or HCC, and responds better to interferon treatment (67). Genotype D may be associated with higher rates of hepatoma and higher rates of post-transplant recurrence and mortality compared with genotype A (66). Genotypes C and D are associated with a lower response to interferon compared with genotypes A and B (67,68). HBV genotype testing can be useful in monitoring and guiding treatment of chronic hepatitis B patients.
All HBsAg-positive patients should undergo a complete assessment with a detailed history including family history of viral hepatitis and HCC, risk factors for hepatitis B acquisition, alcohol use and a complete physical examination to detect signs of chronic liver disease. Laboratory evaluation should include serum ALT/AST, alkaline phosphatase, bilirubin, albumin, international normalized ratio, creatinine and complete blood count (CBC). Specific HBV testing should include HBsAg, HBeAg, anti-HBe and HBV DNA levels. Patients should also be screened for hepatitis C virus (HCV) and HIV infection. Delta virus (hepatitis D virus [HDV]) infection testing should be performed in individuals who have a history of past or current intravenous drug use, or a history of sex with a past or present injection drug user, or from endemic countries with HDV infection. Anti-HDV testing should also be performed in patients with elevated ALT levels but have low to undetectable HBV DNA levels. A baseline abdominal ultrasound should be performed to look for signs of cirrhosis and the existence of HCC. If transient elastography testing is available, it will be a useful test to assess the severity of fibrosis and monitor for disease progression. A liver biopsy should be considered if there is uncertainty of the disease status or if there is a possibility of coexisting liver diseases.
Patients in whom the hepatitis is mild and treatment is not required will still require regular follow-up. These patients with active viral replication are at risk for flare of hepatitis and disease progression over time. ALT levels, liver function tests, HBV DNA and CBC should be monitored at least every six months. Patients who have experienced flares should be monitored more frequently. HBeAg-negative patients who have persistent stable low levels of viral replication (<2×103 IU/mL) can be monitored every six to 12 months. HCC surveillance should be performed on high-risk individuals every six months using abdominal ultrasound (69,70).
Not all HBV-infected patients need treatment. The identification of patients at risk for cirrhosis or HBV infection complications is important so that treatment can be offered to them. The overall objective of treatment in chronic hepatitis B is to prevent the development of cirrhosis and its consequences, liver failure and HCC. The predicting factors that indicate increasing risk of cirrhosis and HCC development include the HBV DNA level, age, significant fibrosis and elevated ALT level. Of these, HBV DNA level has been most extensively studied. Several large-scale, long-term prospective studies have correlated HBV DNA level at baseline with an outcome of cirrhosis and HCC (41–43,71). Persistently elevated HBV DNA levels >4 log10 IU/mL among middle-age (>35 years) male, HBeAg-negative Chinese patients have also been found to have a strong correlation with important clinical outcomes such as cirrhosis and HCC (42). This is likely the case among older HBeAg-positive or negative patients with elevated HBV DNA levels, but probably not among young immune tolerant patients (HBeAg-positive with high HBV DNA levels). The young adults who are in the immune-tolerant phase of HBV infection or who have mild hepatitis have no or minimal liver fibrosis on biopsy (72,73). Therefore, immediate treatment may not be necessary, even with elevated ALT levels. A proportion of these young adults (5% to 10% per year) will undergo spontaneous HBeAg seroconversion. If at any time there is evidence of liver dysfunction or progressive hepatic fibrosis during monitoring, the treatment decision should be readdressed.
HBV DNA levels can fluctuate and the trend in levels is important. For HBeAg-positive patients, treatment should be considered if the HBV DNA is >20,000 IU/mL. HBeAg-positive patients with low levels of HBV DNA may be in the process of HBeAg seroconversion and longer monitoring is important before committing a patient to treatment. In HBeAg-negative chronic hepatitis B patients, HBV DNA levels are usually >3 log10 IU/mL to 4 log10 IU/mL, indicating that the patient may need treatment because this phase of infection is associated with more advanced and progressive liver disease. A liver biopsy or transient elastography testing may be necessary to guide treatment decision in HBeAg-negative chronic hepatitis patients.
Other studies have shown a correlation between ALT level and outcome, but the association was not as strong as for HBV DNA. In particular, patients with ALT levels within the laboratory normal range were also at risk for the development of cirrhosis and HCC when the HBV DNA concentration was >2000 IU/mL. Those who have had the best prognosis have persistently very low ALT values (<40 U/L) (74). These data argue for downgrading the upper limit of normal value for ALT to <30 U/L for men and <19 U/L for women, especially among Asians with HBV (75). In general, any patients with an HBV DNA level >2000 IU/mL, and liver biopsy or noninvasive test showing METAVIR stage 2 or more fibrosis, should be considered for treatment. Figure 1 provides an algorithm for identifying individuals who should be considered for treatment.
HBV genotype has also been shown to be a predictor of adverse outcomes in chronic hepatitis B infection. Most studies were derived from Chinese patients and were thus limited to HBV genotypes B and C. The bulk of the evidence has shown that genotype C is associated with later HBeAg seroconversion and more aggressive liver disease and high rate of progression to HCC (76–78). Similarly, smaller studies from Europe have indicated genotype D is associated with development of cirrhosis. On the other hand, genotype A infection among African patients is correlated with high rates of HCC (79). The HBV genotype may be important in risk prediction, because it seems to influence the natural history of chronic infection.
The treatment decision must also take into consideration the patient’s health status, immune competency, age and the presence of HBV-related extrahepatic diseases. With early treatment and sustained control of HBV, complications related to infection can be avoided.
The goals of chronic hepatitis B treatment are to improve quality of life; to prevent or reverse liver disease progression to liver failure; to minimize the risk of HCC development; and to decrease the risk of transmission. The first-line treatment should be an agent with the highest potency and barrier to resistance. The agent will be able to reduce viremia rapidly to undetectable levels and maintain HBV DNA at undetectable levels continuously. The ability to control HBV with finite duration of treatment will also be important.
For a patient, the choice of first-line therapy should be selected according to the advantages and disadvantages of the available treatments in the setting of the patient’s clinical characteristics (patient’s general health, virus genotype and load) and preference. Although the efficacy of IFN is low and IFN treatment can have significant side effects, IFN treatment can be an ideal treatment for some patients whose clinical characteristics favour a good response to a fixed duration of IFN treatment. Oral nucleos(t)ides are good at suppressing HBV replication and have few side effects. These oral nucleos(t)ides do require prolonged or continuous treatment to maintain the control of HBV. Most hepatitis B patients will have clinical improvement while on oral nucleos(t)ide treatment.
Currently, there are eight approved hepatitis B treatments in Canada. In this section, information on the specific antiviral agents licensed to treat hepatitis B is provided. A summary of the efficacy of the different agents is illustrated in Figure 2 and Table 5.
IFNs are cytokines, which have direct antiviral and immunomodulatory properties. Because of these properties, IFNs could be an ideal treatment for chronic hepatitis B-infected patients; however, the efficacy of interferon treatment in unselected patients is low. The HBeAg seroconversion occurs in 25% to 40% of treated patients (80–84). IFN is less effective in inducing HBeAg seroconversion in patients with high HBV DNA levels (>2×107 IU/mL). The HBeAg seroconversion rates are also reduced in patients with low ALT levels (>2 × the upper limit of laboratory normal). Other predictors of poor response include male sex, age older than 40 years, cirrhosis, and HBV genotype C or D (67). The potential advantages of interferons over nucleos(t)ide analogues include a shorter fixed duration of therapy, the absence of resistance mutations, durable HBeAg seroconversion and a chance of HBsAg seroconversion.
In general, IFN therapy is not recommended for treatment of chronic hepatitis B patients with high viral load and low ALT due to the low response rate. Patients with hepatitis B decompensated cirrhosis should not be treated with IFN because there is a high risk of serious complications such as liver failure and sepsis. Oral nucleos(t)ide treatment should be used in decompensating hepatitis B cirrhotic patients.
The most frequently reported IFN side effects are a flu-like syndrome with symptoms of malaise, fever, fatigue, headache, myalgia and local injection site reaction. These symptoms present early during treatment and often improve over time. The psychiatric side effects of mood changes, insomnia, depression and irritability are variable in severity and often become worse as treatment continues (85).
Since the most recent CASL consensus guidelines on the management of chronic hepatitis B, more information is available that can help select the right patients for IFN treatment and monitoring patients for response while on IFN treatment. This new information is useful to guide the use of IFN in treating HBeAg positive and HBeAg negative chronic hepatitis B patients.
Standard IFN is given subcutaneously at a dose of 10 million IU three times per week or five million IU daily for 16 to 24 weeks (80–84). With standard IFN treatment, the HBeAg seroconversion rate is approximately 30%. PEG IFN alpha 2a and alpha 2b are approved for the treatment of chronic hepatitis B and they can also induce HBeAg seroconversion in approximately 30% of the patients (68,86,87). The optimal duration of PEG IFN (24 or 48 weeks) remains unclear. The addition of lamivudine to IFN-based therapies does not seem to improve overall outcome. The potential role of other nucleos(t)ide analogues in combination with IFN-based therapies are currently being further studied. The goal of therapy (sustained virological response) is to achieve HBeAg seroconversion, normalization of ALT level and maintain HBV DNA level <2000 IU/mL.
The HBeAg seroconversion is durable in 70% to 80% of patients up to eight years of follow-up after IFN treatment (88–94). Delayed HBsAg clearance can occur in IFN-treated patients; however, this is seen in only a minority (<10%) (91). Patients who develop HBeAg seroconversion after IFN treatment have improved survival and complication-free survival (87,94,95).
Analysis of the data sets from the two largest PEG IFN trials on treatment of HBeAg-positive chronic hepatitis has confirmed that genotype A, low viral load and high ALT are predictors of response to interferon (67). Patients with hepatitis B genotype D chronic infection do not respond to interferon treatment. A calculator has been developed to guide the selection of patients for interferon treatment (67).
During PEG IFN treatment, monitoring the decline of HBsAg and HBV DNA levels is useful to further select patients that will benefit from the full course of interferon treatment. If the HBsAg and HBV DNA levels do not decline significantly after 24 weeks of PEG IFN treatment, there is no chance of a sustained virological response and treatment can be discontinued (96,97). Because HBsAg level is not a routine clinical test as this time, HBV DNA level should be checked at weeks 12, 24 and 48. Primary virological nonresponse is <1 log10 decrease in HBV DNA level at week 12 of therapy. Adequate virological response is defined as the decrease of HBV DNA level to <2000 IU/mL, or more than 2 log10 decline in HBV DNA at week 24 of therapy. These definitions and monitoring can help decision making whether PEG IFN treatment should be continued.
In HBeAg-negative chronic hepatitis patients, the treatment response rates with standard IFN are inferior and less durable than responses achieved in HBeAg-positive patients. PEG IFN and standard IFN treatments in HBeAg-negative chronic hepatitis patients have not been compared directly. However, a weekly injection program is preferable to daily or thrice weekly injections when the cost of treatment is equivalent. HBeAg seroconversion cannot be an end point of treatment. Normalization of ALT levels and viral suppression of HBV DNA level to <2000 IU/mL becomes the end point of treatment. With PEG IFN alpha 2a given for 48 weeks, the treatment is effective in suppressing HBV DNA to <20,000 copies/mL (approximately 4000 IU/mL) in 43% of patients (98). The addition of lamivudine to PEG IFN alpha 2a did not improve the viral suppression rate. The durable response rate with undetectable HBV DNA at week 24 post-therapy is <20%. A small number of treatment-responded patients have lost the HBsAg. In a follow-up study of these patients three years later, 28% of PEG IFN-treated patients have HBV DNA levels <2000 IU/mL, indicating that the response can be durable (99). The data do support the use of PEG IFN to treat HBeAg-negative chronic hepatitis.
HBsAg monitoring has been proposed as a tool to monitor PEG IFN treatment response in HBeAg-negative chronic hepatitis B patients. In one study (62), the HBsAg level decline of >0.5 log10 IU/mL at week 12 treatment or 1 log10 IU/mL at week 24 treatment is a good predictor of sustained treatment response and this tool has good positive and negative predictive values. In another study (61), an on-treatment HBsAg decline >1 log10 IU/mL and a week 48 HBsAg level <100 IU/mL are associated with sustained HBV DNA suppression. A week 48 HBsAg level <10 IU/mL is associated with HBsAg clearance three years post-therapy (61). It is not yet clear whether a ‘stopping rule’ can be established at this time. The combined use of HBsAg and HBV DNA level monitoring may offer the solution. The absence of a decrease in HBsAg or a <2 log10 copies/mL decline of HBV DNA at week 12 treatment seems to have a strong negative predictive value of a sustained virological response (62). Patients with neither HBsAg level decline nor more than 2 log10 HBV DNA decline at week 12 treatment will not have a sustained virological response and interferon treatment can be discontinued.
In the following section, information on the specific antiviral agents licensed to treat hepatitis B is provided. Various patterns of response on antiviral therapy are defined in Table 6. A comparison of the relative potency of the different oral antiviral agents in non head-to-head clinical trials is illustrated in Table 5 and Figure 2.
Tenofovir disoproxil fumarate (tenofovir) is the latest oral antiviral approved for chronic HBV infection. Tenofovir is a purine nucleotide reverse transcriptase inhibitor that has shown efficacy in treatment-naïve HBeAg-positive and HBeAg-negative chronic hepatitis B (100). It is licensed for HIV infection, but it also has potent anti-HBV activity. Ongoing large phase 3 studies reported that HBV DNA suppression <169 IU/mL was achieved in 76% and 93% of HBeAg-positive and negative patients after one year of therapy, respectively. Normalization of ALT occurred in two-thirds of patients. HBeAg seroconversion was reported in 25% (year 1) and 49% (year 5) of HBeAg-positive patients. At the end of five years of treatment, 87% of patients overall experienced improvement in liver histology, defined as a >2 point improvement on the Knodell score. Of the patients with cirrhosis at baseline, 75% had at least a two-point reduction in Ishak score after long-term tenofovir therapy (101). Nephrotoxicity and hypophosphatemia with long-term therapy were uncommon, 1.2% and 0.9% of patients, respectively. Importantly, no confirmed cases of antiviral resistant mutation to tenofovir have been documented after five years of treatment (102). Interestingly, HBsAg loss occurred in 11% of patients during the same period (101). An analysis of the Asian subset showed similar efficacy compared with Caucasians. Predictors of HBsAg loss included decline in HBsAg levels on treatment, HBV genotype A and shorter duration of chronic infection (less than four years). Tenofovir is also a drug of choice in HBV/HIV coinfection as part of highly active antiretroviral therapy (HAART) (see section on HIV/HBV coinfection below).
In a study of 266 patients randomly assigned to receive adefovir 10 mg daily versus tenofovir 300 mg daily for one year, 75% of patients who received tenofovir had undetectable HBV DNA compared with only 13% of patients in the adefovir group (100). Normalization of ALT, histological improvement, and HBeAg seroconversion occurred in 68% versus 54%, 74% versus 68% and 21% versus 18% of tenofovir versus adefovir patients, respectively. After 48 weeks, all patients received open-label tenofovir. During the second year of treatment, those who had received adefovir rapidly caught up to the tenofovir group, with similar proportions of patients achieving HBV DNA undetectability (78% and 78%), HBeAg seroconversion (26% and 24%) and even HBsAg loss (4% and 5%). Virological and biochemical responses were maintained with up to five years of continuous treatment; HBeAg loss and seroconversion progressively increased with duration of tenofovir (49% and 40%, respectively) (101).
In another randomized study, 375 HBeAg-negative patients were randomly assigned to receive adefovir or tenofovir. Similar to the HBeAg-positive trial, a significantly higher proportion of patients receiving tenofovir achieved undetectable HBV DNA levels compared with patients receiving adefovir (93% versus 63%, respectively). However, ALT normalization (76% to 77%) and histological improvement (69% to 72%) were similar between the two groups. During open-label tenofovir from year 2 onwards, almost all patients achieved undetectable HBV DNA (100).
Tenofovir also appears to be effective for the treatment of lamivudine-resistant HBV patients. Although phase 3 randomized trials using tenofovir or tenofovir plus emtricitabine (Truvada, Gilead Sciences, USA) are ongoing, retrospective studies of tenofovir with or without ongoing lamivudine have reported high rates of viral suppression in patients with documented rtL180M ± rtM204V/I mutation (102,103). It remains unclear whether ongoing lamivudine needs to be continued in these patients, but a brief period of overlap (six months) with lamivudine is reasonable. These studies have led to rapid adoption of tenofovir as the treatment of choice for lamivudine-resistant HBV.
Clinical data on the use of tenofovir for treatment of patients with adefovir-resistant HBV are lacking. Tenofovir appears to have reduced efficacy in patients with documented adefovir-resistant mutation (rtN236T) due to partial cross-resistance (104). In this situation, combination tenofovir plus emtricitabine may be more effective. In those with rtA181V, the response to tenofovir appears to be preserved, suggesting that confirmation of specific antiviral-resistant mutations is important before institution of salvage therapy.
Entecavir is a selective guanosine analogue and a potent inhibitor of HBV DNA replication. It has been shown to be more effective than lamivudine in terms of viral suppression in treatment-naïve patients (105). Entecavir was well tolerated and had a similar side effect profile to lamivudine in large clinical trials. In treatment-naive patients, HBeAg seroconversion at one year is similar to other nucleoside analogues at 21% after year 1 and 39% after year 3 (Table 5) (105). Only 1% to 2% of subjects developed resistance to entecavir after five years (106). However, this is in contradistinction to those with previous lamivudine resistance, who develop entecavir resistance at high rates after one year of entecavir (8%). Resistance to entecavir requires the presence of the YMDD mutations that confer resistance to lamivudine, and also requires the presence of one of two or three additional mutations (107). These additional mutations in isolation do not confer resistance to entecavir. Therefore, pre-existing lamivudine-resistant entecavir-treated patients are at risk of developing resistance to entecavir (106). For this reason, entecavir should not be used to rescue patients with lamivudine-resistant HBV.
In a large phase III study, 715 patients were randomly assigned to entecavir 0.5 mg versus lamivudine 100 mg. Entecavir-treated patients had higher rates of HBV DNA undetectability (67% versus 36%) and histological improvement (72% versus 62%) compared with the lamivudine group. However, HBeAg seroconversion rates were comparable between the groups (11% to 12%) after one year of treatment (108).
In another phase III study of 648 patients (109), in which entecavir was compared with lamivudine, virological suppression and histological improvement were significantly higher in entecavir-treated patients (90% versus 72% and 70% versus 61%, respectively) (109).
Two hundred eighty-six HBeAg-positive patients with persistent viremia on lamivudine were treated with high-dose entecavir (1 mg daily). Only 20% of patients achieved undetectable HBV DNA after one year of treatment, and 8% of patients subsequently developed resistance to entecavir, and this rate increased substantially with prolonged duration of therapy (110). Thus, entecavir is not recommended as salvage therapy for lamivudine-resistant HBV.
Lamivudine is a pyrimidine nucleoside analogue inhibitor of the HBV polymerase. It was the first oral agent approved for the treatment of HBV in Canada and until 2006 was the only such agent available. Thus, many HBV patients may have received lamivudine in the past and many patients who have recently immigrated from southeast Asia have been exposed to lamivudine, where the drug is still widely used. Generally, lamivudine is effective at reducing HBV DNA levels and has established long-term safety (111). The relative potency of lamivudine compared with other antivirals is reported in Figure 2. However, the major disadvantage of lamivudine is the very high risk of developing antiviral resistance, approaching 70% at four years (112). Furthermore, the development of lamivudine resistance may lead to cross-resistance to other agents such as entecavir and telbivudine and limit future treatment options. Therefore, lamivudine is no longer a suitable first-line treatment for hepatitis B, but may still have a limited role in certain situations in which time-limited therapy is indicated such as treatment of immune tolerant pregnant HBV carriers, or as prophylaxis for those undergoing short-term immunosuppression.
Lamivudine was shown to reduce progression of liver disease and possibly hepatoma in HBV cirrhotic patients compared with placebo in a randomized study (113,114). The benefit of treatment was diminished in those who developed lamivudine resistance and virological breakthrough, indicating the importance of viral suppression and avoidance of resistance. Other agents that induce potent viral suppression have also been shown to improve long-term outcomes (113).
Adefovir dipivoxil is a nucleotide analogue. Adefovir is a less potent agent and does not achieve complete viral suppression in the majority of patients within the first year, possibly due to the low approved daily dose (10 mg). Risk factors for adefovir resistance are high baseline viral load and inadequate suppression of virus on therapy (115,116). Side effects of adefovir include nephrotoxicity, hypophosphatemia and, rarely, Fanconi syndrome. Therefore, renal function (estimated glomerular filtration rate) should be monitored at baseline and every three months during therapy. Adefovir add-on therapy is useful in patients with lamivudine resistance (117), although tenofovir has become the treatment of choice in this situation.
Telbivudine is a beta L-nucleoside analogue with relatively potent antiviral efficacy against HBV. Telbivudine was more effective than lamivudine in treatment-naive HBeAg-positive and HBeAg-negative chronic hepatitis B (118). However, genotypic resistance rates of 5% and 11% were reported after one and two years of telbivudine, respectively (118,119). Asymptomatic rises in creatine kinase and symptomatic myositis occurred in approximately 12% of patients. Due to these disadvantages, telbivudine is not considered first-line therapy for chronic hepatitis B in North America. However, the drug is available in many Asian countries and recent immigrants may have been exposed to telbivudine.
Telbivudine may have a limited role for short-term treatment of the pregnant HBV carrier with high viral load, because it is classified as Food and Drug Administration (FDA) class B in pregnancy. In a recent study of 229 pregnant HBV carriers in China, telbivudine given in the second or third trimester of pregnancy was effective in suppressing HBV DNA levels and reducing the risk of perinatal transmission of HBV (0% versus 8% HBsAg-positive in telbivudine versus placebo infants with seven months’ postpartum follow-up (120).
Emtricitabine (FTC) is a pyrimidine nucleoside analogue, with a spectrum of activity and resistance profile that is very similar to lamivudine (3TC) (121,122). Although it is licensed for use in combination with tenofovir (Truvada, Gilead Sciences Inc, USA) in Canada for HIV, it is not licensed for use as monotherapy in HBV infection.
Although combination therapy for hepatitis B may be appropriate in certain patient populations, there remain little data to support routine use in treatment-naïve patients. In a single-centre study, in which combination lamivudine plus adefovir was compared with lamivudine alone, no difference in HBV DNA suppression, HBeAg seroconversion or ALT normalization was observed (123). However, resistance to lamivudine was significantly lower in the combination group compared with the monotherapy group. On the other hand, combination lamivudine plus telbivudine was less effective than telbivudine alone for all end points (124), possibly due to antiviral antagonism. In a randomized open-label study of entecavir plus tenofovir versus entecavir alone (125), combination therapy was not more effective in reducing HBV DNA levels or in inducing HBeAg seroconversion overall. However, in the subset of patients with baseline HBV DNA >8 log10 IU/mL, combination therapy was more effective in reducing HBV DNA <50 IU/mL (79% versus 62%, P=0.04) (125). In cirrhotic patients, particularly those with hepatic decompensation, the development of resistance to antiviral agents may lead to fatal flares of liver disease. Therefore, combination therapy can be considered in this setting (126). Suggested regimens include lamivudine plus tenofovir, tenofovir plus emtricitabine or tenofovir plus entecavir.
Patients treated with nucleos(t)ide analogues should be monitored with HBV DNA and ALT initially every three months on treatment, and every six months once aviremia is achieved. This is to confirm an initial fall in HBV DNA level, and in the case of lamivudine, telbivudine and adefovir, to determine whether treatment with the same drug can be maintained, or whether another drug should be added or substituted (127). HBV DNA levels must be monitored regularly to allow for early detection of viral breakthrough leading to resistance. Patients on nucleotide agents require monitoring of renal function and serum phosphate levels every three to six months. Patients receiving telbivudine require monitoring of creatine kinase levels. Patients must continue to be screened for HCC as per current guidelines (Table 7), irrespective of response to antiviral treatment.
The traditional end point of oral antiviral therapy for HBeAg-positive patients is HBeAg seroconversion. The probability of HBeAg seroconversion is similar across the various agents (approximately 20% in year 1) and increases to 40% to 50% after five years of continuous therapy. An additional 12 months of consolidation therapy following HBeAg seroconversion is recommended to reduce the risk of virological relapse following seroconversion. The durability of oral therapy is approximately 75%. Ongoing treatment is recommended for those patients who have not yet achieved HBeAg seroconversion.
For HBeAg-negative patients, the duration of therapy is somewhat undefined. Predictors of a durable response have been difficult to identify in clinical studies. Therefore, the majority of these patients will require long-term therapy. The ultimate, yet difficult-to-achieve end point, in this category of patients is HBsAg loss or seroconversion. HBsAg loss was reported in 12% and <1% of HBeAg-positive and HBeAg-negative patients receiving continuous tenofovir therapy, respectively.
Mutations that confer resistance to antiviral agents may occur spontaneously and are not caused by the antiviral agents. Most resistant mutants have diminished replication competence and do not survive. However, in the presence of a selective pressure that inhibits the growth of wild-type virus, proliferation of some mutant virus species occurs until they come to be the dominant species. Depending on replication competence, mutants can replicate at high levels over time. Clinically, antiviral resistance is suspected when serial HBV DNA testing shows increases in viral load of more than 10-fold (1 log10 IU/mL) compared with nadir (128). Thus, monitoring for antiviral resistance requires regular assessment of HBV DNA concentrations. When resistance develops, particularly to lamivudine, secondary mutations may occur that may reduce susceptibility to other antivirals (129). Genotypic resistance can be detected by various methods, such as population sequencing, reverse hybridization, clonal analysis and ultra-deep sequencing methods. Sequencing requires that the mutant virus be present in at least 20% to 25% of the viral population. Reverse hybridization (line probe assay) is more sensitive in detecting mutants at a lower level (5% total viral population) (130). A working knowledge of common HBV polymerase mutations is necessary, due to the cross-resistance, which will limit future treatment options.
The development of resistance to antiviral therapy is not benign. There is considerable evidence that the benefits of viral suppression are lost (131). Acute flares of hepatitis related to lamivudine- or adefovir-resistant HBV can occur, and this may be fatal, particularly in cirrhotic patients. The development of resistance is a strong indication to change therapy. It is not acceptable for patients with lamivudine resistance to continue to be treated with lamivudine monotherapy when effective alternatives exist.
All nucleos(t)ide analogues are associated with the development of resistance. The rate at which antiviral resistance to individual agents develops has not been accurately defined, because long-term studies are lacking and resistance was evaluated only in small subgroups of patients that were initially recruited into trials. Nonetheless, rates of antiviral resistance from non-head-to-head studies for various agents are compared in Figure 3.
Specific antiviral-resistant mutations in the HBV polymerase gene that are associated with resistance to various agents are shown in Table 8(132). Risk factors for antiviral resistance were determined mainly from studies of lamivudine, due to the high rate of resistance. These included high baseline HBV DNA, lack of virological response after six months of treatment, and prolonged duration of therapy and prior antiviral resistance. In a trial of telbivudine versus lamivudine, those who failed to achieve undetectable HBV DNA at six months of telbivudine were at risk of telbivudine resistance at one and two years and were less likely to achieve HBeAg seroconversion (133). Thus, switching to more potent therapy is recommended in those who fail to achieve a virological response after six months of medium potency therapy such as lamivudine or telbivudine (127).
Early detection of antiviral resistance is important to avoid ALT flares and decompensation of liver disease. In a study of 74 patients with lamivudine resistance, early institution of adefovir add-on therapy when HBV DNA was <6 log10 copies/mL was associated with higher rates of HBV DNA resuppression and lower rate of ALT flares, compared with the group in which HBV DNA was >6 log10 copies/mL (117). Therefore, treatment is more likely to be effective if a new agent is introduced when the viral load is low than when it is high. To detect early virological breakthrough, HBV DNA levels should be monitored every three to six months depending on the agent used. Antiviral resistance testing is recommended in those with confirmed virological breakthrough to differentiate true antiviral resistance from medication nonadherence.
Primary nonresponse is defined as a <1 log10 reduction in HBV DNA at week 12 or <2 log10 reduction in HBV DNA at 24 weeks of antiviral therapy (127). Antiviral testing is recommended to rule out resistance, which may predate the start of treatment. Medication adherence should be questioned and counselling for those found to be nonadherent. Occasionally, there may be problems with absorption, medication dose or other pharmacological reasons for nonresponse, but these are poorly defined and difficult to confirm.
For those receiving therapy with less-potent agents such as lamivudine or adefovir, treatment can be switched to a more potent agent such as tenofovir or entecavir (in the absence of lamivudine resistance) at 24 weeks, and HBV DNA repeated in three months. Primary nonresponse is extremely uncommon in those receiving tenofovir or entecavir as first-line therapy.
Previous studies demonstrated that addition of adefovir after virological breakthrough, but before clinical breakthrough (ie, when the viral load is still low), is one option (117). Switching to adefovir monotherapy is associated with a high rate of adefovir resistance (20% after one year) and is not recommended (131,134,135). However, more recent restrospective studies have shown tenofovir monotherapy is also effective as salvage therapy for lamivudine resistance (103,104). Rapid HBV DNA suppression occurs in most patients and there were no reports of tenofovir resistance among lamivudine-resistant HBV patients. Phase III studies of tenofovir compared with tenofovir/emtricitabine for lamivudine-resistant HBV are still under way. Entecavir is not an acceptable choice for lamivudine resistance because the response to entecavir is reduced and the risk of entecavir resistance is high (32% after three years) (136). Lamivudine-resistant HBV is cross-resistant to telbivudine and also to emtricitabine. Table 9 illustrates the relative activity of specific antiviral agents in the setting of antiviral drug resistance.
Genotypic resistance to adefovir monotherapy is rare in the first one to two years of therapy but progressively increases to approximately 29% of patients after five years of continuous therapy (137). Virological breakthrough on adefovir has been associated with adverse clinical outcomes such as decompensation of liver disease (130). Lamivudine, telbivudine or entecavir are all acceptable choices for salvage therapy. However, there are no large studies confirming the efficacy of these agents, but in vitro data support their use. Tenofovir is also believed to be effective in adefovir-resistant HBV, but there are reports of reduced efficacy of tenofovir in the setting of rtN236T mutation, which reduces its susceptibility (104). Thus, confirmation of specific mutations to adefovir is important before switching antiviral therapy.
Entecavir has a very high genetic barrier to resistance. Entecavir resistance requires a lamivudine-resistant backbone (YMDD mutation). YMDD mutation alone decreases entecavir potency, but is not enough to produce resistance. Nonetheless, the presence of rtM204V and rtL180M, and one or more additional mutations (rt169T, rtT184G, rtS202I, rtM250V), is able to confer resistance to entecavir (138). However, in the absence of the rtM204V and rtL180M mutations these additional mutations are not associated with any decrease in potency. In the registration studies of entecavir in lamivudine-resistant patients, entecavir-resistant mutations were detected in a proportion of patients at baseline before the introduction of entecavir (138). As a result, genotypic resistance was identified in 7% and viral breakthrough in 1.6% patients at the end of the first year of therapy (138). This increased to more than 30% at the end of the third year of therapy. By contrast, in nucleoside-naïve subjects, resistance to entecavir occurred in approximately only 1% to 2% of patients after three years (107). Entecavir resistance can be treated with either adefovir or tenofovir (based on in vitro data only).
Little is known about treatment of resistance to telbivudine, which occurs in 18% of patients at the end of two years of therapy (124). Resistance is mainly mediated by the rtM204I mutation and uncommonly by other mutations. Therefore, cross-resistance with lamivudine and emtricitabine can be expected. Adefovir and tenofovir may be used for telbivudine-resistant HBV, but entecavir should be avoided as in the case of lamivudine resistance.
Tenofovir has a very high genetic barrier to resistance. To date, there have been no confirmed cases of tenofovir resistance in HBV monoinfected patients after three to five years of continuous therapy (102). In fact, there is no known signature mutation for tenofovir in the HBV polymerase gene. A case report documented rtA194T substitution in an HIV/HBV coinfected patient (139), but this mutation has not been reported in HBV monoinfected patients and is likely not clinically significant. In registration trials of tenofovir, among 4% of patients who did not achieve undetectable HBV DNA, population sequencing to detect resistance revealed no conserved site changes, although resistance surveillance is ongoing.
Elevated HBV DNA levels have been shown to predict flares of viral hepatitis. Because the vast majority of patients are asymptomatic even during flares, attention to regularly scheduled blood work and abdominal ultrasound is necessary. Although each individual flare may be short lived and not significant on its own, cumulative necroinflammation and fibrosis develop with repeated flares of disease. Because the period of ALT elevation may be brief, frequent testing is necessary. Monitoring should include HBV DNA, HBsAg and HBeAg, ALT, liver enzymes, tests of liver function and CBC.
The annual incidence of hepatoma in HBV-infected individuals without cirrhosis is 0.4% to 0.6% in Asians, 0.2% in Alaskan natives and approximately 0.3% in Caucasians (140–143). There are insufficient data on the incidence of HCC in Africans or North American blacks. In cirrhosis, the incidence of HCC development is >2% per year, with a cumulative five-year incidence from 15% to 20% (69). Not all patients with hepatitis B are at equal risk of developing HCC. Known risk factors for hepatoma include male sex, family history, high-level viral replication, elevated ALT levels, HBeAg-positive status, HBV genotype C, hepatitis C and/ or hepatitis D and/or HIV coinfection, and concomitant liver disease such as alcoholic liver disease and nonalcoholic fatty liver. A nomogram based on the Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer-Hepatitis B Virus (REVEAL-HBV) database was recently published and incorporates all of the above risk factors to allow for risk stratification (144). Another model for prediction of HCC has been developed and validated in cohorts of Chinese patients (145).
Surveillance should be performed every six months using abdominal ultrasound in those deemed to be at high risk for hepatoma (69). Alpha-fetoprotein testing is not an effective screening method (146), and is not recommended as a screening modality for HCC.
The categories of patient who should be screened are presented in Table 7.
All patients with well-compensated cirrhosis should be considered for therapy if the HBV DNA level is >2000 IU/mL whether they are HBeAg or anti-HBe positive (114). If the HBV DNA is lower than this threshold, patients may be observed closely with measurements of HBV DNA and ALT every three to six months or they may be considered for therapy. Standard interferon or PEG IFN may be used with caution in these patients, but nucleos(t)ide analogues are preferred. Nucleos(t)ide analogue treatment should continue indefinitely in patients with cirrhosis, even if such patients undergo HBeAg seroconversion. A suggested algorithm for the management of hepatitis B cirrhosis is shown in Figure 4.
All patients with hepatic decompensation due to hepatitis B should be treated with nucleos(t)ide analogues – regardless of HBV DNA concentration – to either suppress viral replication, or prevent possible flares in disease activity. Such patients should be considered for liver transplantation and selection of the appropriate HBV therapy should be made in consultation with the local liver transplant program. Lamivudine and adefovir have been shown to improve hepatic function in such patients and may stave off the need for liver transplantation (147–149). However, the development of resistant mutants can be associated with flares of hepatitis and hepatic decompensation. Thus, it is preferable to use drugs (entecavir or tenofovir) with the lowest rates of resistance. Combination adefovir plus lamivudine is an option. Another alternative is the combination of tenofovir and emtricitabine, which is available as a single tablet for daily use. In a study of 112 HBV patients with decompensated cirrhosis (126), a higher proportion of patients receiving tenofovir plus emtricitabine achieved HBV DNA <400 copies/mL and HBeAg seroconversion compared with those who received tenofovir or entecavir monotherapy. However, liver function improved in all patients (126). The renal function must be monitored carefully if tenofovir or adefovir are used in cirrhotic patients because these patients are prone to renal dysfunction.
Since the last consensus update, additional data for patient groups with special needs became available. The consensus committee has updated the guidelines for the special patient population to assist clinicians and health care providers in providing health services and treatment to these groups of patients.
Due to similar transmission routes, coinfection with HBV in patients with HIV is common. There are approximately 40 million HIV-infected people worldwide and it is estimated that approximately 10% (ie, approximately four million) of HIV-positive persons also have chronic hepatitis B (150,151). Based on a 2008 modelling studies and literature review (152), the epidemiology of HBV and HIV coinfection in Canada is poorly defined. It is estimated that of 16,000 HIV-positive persons, approximately 6400 (9.8%) are coinfected with HBV (152). HIV coinfection increases the risk of liver decompensation, cirrhosis and HCC. HBsAg and HBeAg seroconversion rates are reduced and HBV DNA levels are higher (153). French mortality studies describe an increasing proportion of liver-related deaths (13.4% to 15.4%) in persons with HIV over a five-year interval (2000 to 2005), with a concomitant increase in deaths from HCC from 15% to 25% (154). The Multicenter AIDS Cohort study reported a 19-fold increase in liver-related mortality in HBV/HIV coinfected patients compared with HIV monoinfected patients (155). A meta-analysis performed on data from 12,382 patients enrolled in 11 studies revealed a significant effect of HIV/HBV coinfection on mortality both before and after commencement of HAART (156).
Currently approved anti-HBV oral nucleos(t)ide analogues with anti-HIV activity include lamivudine, telbivudine, emtricitabine, tenofovir and entecavir (157–160). In HIV coinfected persons on long-term lamivudine (without a second anti-HBV drug), the rate of lamivudine-resistant HBV is approximately 90%, potentially leading to severe hepatitis and fatalities (161,162). Entecavir is active against HIV and when given as monotherapy can result in the HIV lamivudine resistance mutation (rtM184V), limiting HIV therapeutic options (158). Regardless, given its overall trivial activity against HIV, HIV providers would not choose entecavir because it would not improve the potency of an anti-HIV regimen. For HBV and HIV coinfection, tenofovir plus either lamivudine or emtricitabine is usually recommended in HAART. If tenofovir is contraindicated (such as due to chronic kidney disease), then entecavir should be added; however, due to cross-resistance, the durability of entecavir against HBV may be compromised by previous HBV treatment failure with regimens including emtricitabine or lamivudine (163). Several international expert guidelines including the United States Department of Health and Human Services, the International AIDS Society, the European AIDS Society and the British HIV Society state that antiretroviral treatment should be initiated, regardless of CD4 T cell count, in patients with HBV coinfection when treatment of HBV is indicated (164–166). If HAART with anti-HBV activity is stopped for any reason, an anti-HBV agent should be added to avoid HBV reactivation and hepatocellular disease flares (167–169). Immune reconstitution syndrome in advanced HIV disease may occur after initiating HAART, and could result in a flare of hepatitis due to increased immune-mediated hepatocellular injury (170,171).
The treatment of the HBV and HIV coinfected individual is complex and, ideally, these patients should be managed with a multidisciplinary approach by specialists with an understanding of both infectious disease and liver disease. The baseline status of both HBV and HIV infection needs to be clearly defined, including routine laboratory tests for HIV (ie, CD4 T cell count, HIV RNA plasma viral load, etc). Other recommended tests include creatinine (estimated glomerular filtration rate), liver enzymes and liver function tests, and a CBC. The assessment of HBV status is as noted above and should include HBV DNA, HBeAg, anti-HBe, hepatic synthetic function, liver enzymes, abdominal ultrasound, and assessment of liver disease via noninvasive modalities (ie, transient elastography or FibroScan) or liver biopsy if transient elastography is not available. Baseline renal function including creatinine (estimated glomerular filtration rate) and urinalysis should be assessed given the possible association between tenofovir and chronic kidney disease and decreased bone mineral density in the HIV-positive population (172). Of note, patients with evidence of past infection to hepatitis B (anti-HBc- and anti-HBs- or anti-HBe-positive) should be tested for HBsAg alone at yearly intervals to detect a possible reactivation. Patients with isolated anti-HBc should be vaccinated and vaccine nonresponders should be tested yearly for HBsAg, anti-HBc and anti-HBs to identify new infections (173).
Dual infection with HBV and HCV can also occur due to shared parenteral routes of transmission. HCV, like HBV, is a hepatotropic pathogen and available natural history studies suggest that HBV/HCV coinfection increases the risk of progressive liver disease including cirrhosis and HCC (174–183). Recent in vitro studies using novel cell-culture systems have shown that HBV and HCV can replicate within the same hepatocyte without direct viral interference (184,185), suggesting that indirect mechanisms mediated by host immunity likely determine disease dominance and outcome. Currently, there are no standard of care recommendations for treatment of HBV/HCV coinfection. The dynamic nature of both infections warrants ongoing monitoring (186,187). All patients should have complete assessment of liver disease severity and HBV DNA and HCV RNA measurements. The dominant viral infection should be the focus of treatment. Subjects with high levels of HBV DNA but negative HCV RNA should be treated as any other HBV-infected patient. If the HBV/HCV coinfected patient appears to have inactive chronic hepatitis B, or occult hepatitis B, and the HCV RNA is positive, these patients should be treated as for other patients with chronic HCV infection. In the largest clinical trial published to date on treatment of HBV and HCV confection (188), the rates of HCV sustained virological response to PEG IFN and ribavirin was similar between HBV/HCV coinfected compared with HCV monoinfected patients. However, as have been reported in a number of published case series, the authors also observed a high percentage of HBV reactivation during treatment-induced suppression of HCV (189,190). Therefore, if the patient has detectable HBV DNA, these patients should be considered for combination anti-HCV therapy with anti-HBV nucleos(t)ide analogue therapy (ie, entecavir or tenofovir). If this is not possible, HBV DNA levels should be monitored every four weeks while on anti-HCV therapy and treatment instituted in patients with HBV flares. Finally, therapeutic trials evaluating combinations of HCV antivirals, especially with the newer protease or polymerase inhibiters along with anti-HBV nucleos(t)ide analogues are necessary to establish the optimal regimen for treatment of HBV and HCV coinfection.
Decisions on antiviral therapy in women of childbearing age must take into account the woman’s desire for a family. Due to its finite duration of treatment, PEG IFN may be an attractive option in these women, especially if they have other favourable characteristics and no contraindications for interferon therapy (ie, low viral load, high ALT, genotype A or B), if the patient agrees to delay pregnancy until after completion of the 48-week treatment course. Women needing immediate HBV treatment and planning a family should be treated with drugs that are safe in pregnancy (see below).
If a patient becomes pregnant while already on anti-HBV therapy and has not achieved the necessary virological or biochemical end points of treatment, then it is recommended that treatment be continued throughout pregnancy but with an antiviral agent that is considered safe to use during pregnancy (see below). Treatment should be continued until the same treatment goals are achieved as in nonpregnant women.
Initiation of anti-HBV therapy may be considered in pregnancy for two main reasons. First, a small proportion of HBV-infected women may have liver disease that merits treatment. Second, there is evidence that administration of anti-HBV therapy in late pregnancy to women with high concentrations of HBV DNA can reduce the risk of mother-to-infant transmission (ie, vertical transmission) greater than that provided by passive-active immunoprophylaxis with combined hepatitis B immune globulin (HBIG) and HBV vaccination. The most common route of HBV infection globally is vertical transmission, mainly during parturition. The majority of infants infected become chronic carriers and remain at subsequent risk for future liver disease. As shown in the 1980s, administering both HBIG and HBV vaccine to infants born to HBV-infected women is >90% effective in preventing mother-to-infant transmission, justifying universal screening of pregnant women for HBsAg, and passive-active immunoprophylaxis of all infants at birth (191,192). However, it is estimated that there is still an approximately 10% residual risk of HBV vertical transmission despite administration of both HBIG and HBV vaccine with HBeAg positivity and high levels of plasma HBV DNA being the main virological predictors of prophylaxis failure (193). If maternal HBV DNA is >109 copies/mL, the risk may be as high as 32%. In one study of Australian pregnant women with chronic hepatitis B (194), no transmissions were observed in 91 cases when maternal HBV DNA was <108 copies/mL (194). However, in other studies of HBeAg-positive mothers, the residual risk of HBV mother-to-infant transmission despite HBIG and vaccination is estimated to be approximately 15% (191,193,195–197). Pan et al (198) presented data at the 2011 Annual American Association for the Study of Liver Disease (AASLD) meeting and reviewed the outcomes in >1000 HBeAg-positive pregnant women. Vertical transmission was defined as infant HBsAg positivity at seven to 12 months of age. The maternal predelivery HBV DNA levels were stratified and correlated with the corresponding infected rates at birth. In 1068 consecutive infants born to HBeAg-positive mothers receiving standard passive-active immunoprophylaxis, 61 of 1068 infants were HBsAg positive at seven to 12 months of age (approximately 5% immunoprophylaxis failure rate). No cases of vertical transmission occurred when maternal HBV DNA was <6 log10 copies/mL (approximately 2×5 log10 IU/mL) (Table 10). Other maternal risk factors include mothers with postpartum hemorrhage, meconium-stained amniotic fluid and oligohydramnios (198). Infant factors included HBV DNA venous blood, high HBsAg levels and absence of anti-HBs at birth (199).
There is convincing evidence that anti-HBV therapy reduces the risk of HBV mother-to-infant transmission. One randomized controlled trial (RCT) from China and a case-control study from the Netherlands demonstrated the efficacy of anti-HBV therapy in late pregnancy added to HBIG and HBV vaccine in the prevention of mother-to-infant transmission of HBV with lamivudine (200,201). Similarly, a recent case-control study has demonstrated the efficacy of telbivudine (120) (Table 11). RCT and case-control data are not available with the two most potent HBV nucleoside inhibitors, entecavir and tenofovir.
The optimal gestational age to start anti-HBV therapy has not been established. The higher the HBV DNA, the longer it takes to suppress; however, full suppression is not likely necessary, given the efficacy of HBIG and vaccine at low levels of maternal viremia. The RCT of lamivudine started therapy at week 32 of gestation with a 2.63 log10 decrease in HBV DNA at delivery (200). The case-control study of telbivudine started therapy between week 20 and 32 of gestation with a 5.72 log10 decrease in HBV DNA at delivery (120). A recent abstract presented by Han et al at the 2011 AASLD meeting has shown that initiation in the third trimester was just as effective as in the second trimester (202). Thus, the consensus meeting agreed that in the majority of cases (ie, no signs of threatened preterm delivery and possible intrauterine transmission), initiation in the last trimester of pregnancy (after 28 weeks) is reasonable to lower maternal viremia before parturition.
When considering choice of antiviral therapy during pregnancy, the FDA has classified tenofovir, telbivudine and emtricitabine as pregnancy category B (no evidence of risk to humans according to adequate well-controlled studies), and lamivudine, entecavir and adefovir as category C drugs (risk cannot be ruled out) (203). Data from the June 2011 antiretroviral pregnancy registry for nucleoside analogue exposure in the first trimester indicate that there is overall minimal teratogenic risk (204). According to prescribing information, it has not been recommended that mothers breastfeed their infants while taking oral nucleos(t)ide analogues (205,206). Although some studies show that nucleoside analogues are secreted at minimal or extremely low levels in breastmilk (ie, 0.03% of the recommended infant dose of tenofovir) and can be safely used (207,208), the consensus position is that breastfeeding is not recommended if receiving anti-HBV nucleos(t)ide analogue therapy. Thus, if treatment is only indicated to prevent vertical transmission, and if the mother wishes to breastfeed, antiviral treatment should be stopped after delivery due to unknown potential risk. However, mothers should be followed for possible virological and biochemical flares after stopping the nucleos(t) ide analogue. Breastfeeding is not contraindicated for infants born to HBsAg-positive mothers and is encouraged by the Canadian Paediatric Society and the American Academy of Pediatrics (209,210). The risk of HBV transmission is low and comparable for breastfed and formulafed infants after administration of HBIG at birth followed by HBV vaccination (211–213).
Finally, a number of practical issues should be considered in using oral anti-HBV therapy in highly viremic pregnant women. Such use may still be considered ‘off-label’ and the development of antiviral resistance has not been studied in this setting. Although lamivudine is recommended by other expert guidelines, vertical transmission has been reported despite maternal therapy (214). There is extensive experience with both tenofovir and lamivudine use in HIV-positive pregnant women and in breastfeeding. It seems logical to choose tenofovir as primary treatment given its better resistance profile, and because the indication is to reduce high maternal viral load. Thus, the consensus recommended tenofovir as first-line treatment during pregnancy, telbivudine or lamivudine is an alternative if tenofovir is contraindicated. In all cases, an informed discussion with such patients is warranted, including presenting the pros and cons of antiviral therapy. If treatment is not initiated during pregnancy or if treatment is stopped after delivery, the mother should be closely monitored for hepatocellular disease flares.
Renal involvement is one of the most common extrahepatic manifestations of HBV infection, and usually manifests as immune complex-associated glomerulopathy, such as membranous glomerulonephritis, membranoproliferative glomerulonephritis, mesangioproliferative glomerulonephritis and immunoglobulin A nephropathy, as well as other extrahepatic diseases such as vasculitis and polyarteritis nodosa (215,216). Suppression of HBV DNA can result in improved renal function in these patients. There is evidence that patients with HBV-induced immune-complex mediated disease may have increased rates of responsiveness to interferon therapy or nucleos(t)ide analogues (217–225). Most cases reports are with lamivudine but withdrawal of antiviral therapy can lead to relapse of nephrotic syndrome and, as noted, long-term lamivudine treatment is limited by the potential emergence of drug-resistant mutations and hepatic flares (221,226). There is one case reported on entecavir therapy for hepatitis B-related membranous nephropathy, which may be an option especially if prolonged treatment courses are required (227). Tenofovir (and adefovir) should be used with caution in this population, because these drug classes may be associated with renal dysfunction. Because all antiviral agents are excreted by the kidney, dose adjustments are required in renal failure.
Reactivation of HBV is defined as an increase in hepatitis B viral replication in patients with serum HBsAg-positive chronic hepatitis B or in patients with resolved (past) HBV infection (228,229). The latter scenario may be due to occult hepatitis B infection, which is characterized by the presence of low-level HBV DNA in serum, liver and peripheral blood mononuclear cells detected by highly sensitive kinetic PCR assays, despite serum HBsAg negativity. Often, anti-HBc is the sole serological marker of occult hepatitis B infection (230,231). HBV reactivation can occur spontaneously, especially in HBeAg-negative chronic hepatitis B, or be a result of immunomodulatory therapy. Examples of the latter scenario include cancer chemotherapy, treatment with rituximab (due to its effect on humoral immunity), HIV-related immunosuppression of cellular immunity, corticosteroid therapy (especially because the HBV enhancer has glucocorticoid-dependent activity), immune modulation for autoimmune conditions, solid organ transplantation (heart, lung, kidney) and bone marrow transplant recipients (232–237). The reactivation of HBV replication in occult hepatitis B can lead to so-called reverse seroconversion, development of serum HBsAg positivity and active hepatitis B infection. It should be noted that even the presence of anti-HBs is not protective, although the risk of reactivation is significantly lower in occult hepatitis B infection compared with chronic hepatitis B (238). Occult hepatitis B reactivation has been described in HIV-related immunosuppression and in solid organ transplantation, but most of the data are from case reports within the oncology literature due to intense immunosuppression such as regimens involving rituximab-steroid combination with an overall estimated risk of 3% (239–243). Recent multisite American data presented at the AASLD 2011 meeting of >10,000 cancer patients receiving chemotherapy reported that nearly one-quarter of cancer patients that were either HBsAg- and/or anti-HBc-positive had reactivation of HBV. Only a small percentage underwent HBV screening before reactivation and/or received HBV prophylaxis. Furthermore, patients who received prophylaxis had a dramatically lower all-cause mortality (22%) compared with those treated after reactivation (72%) (244). Thus, persons at risk for HBV are not being adequately screened before chemotherapy, resulting in preventable reactivation.
Typically, HBV reactivation begins with a sudden increase in viral replication during immune suppression (229). Diagnostic markers of this phase are an increase in serum HBV DNA more than one log above baseline, anti-HBc immunoglobulin M and HBeAg. The second phase develops when immunosuppression is withdrawn. Immune restoration is followed by a rapid immune-mediated destruction of HBV-infected hepatocytes leading to acute liver failure, chronic hepatitis or cirrhosis. Diagnostic markers of this phase are aminotransferase levels three times above the upper limit of normal, and even jaundice.
The consequences of HBV reactivation in HBsAg-positive chronic carriers include subtle changes in transaminases to fulminant hepatic failure and even death without liver transplantation (229). The mortality from HBV reactivation ranges from 4% to 60%, with the greatest risk related to hematological malignancies. Therefore, all HBsAg-positive patients should receive anti-HBV prophylaxis with a nucleos(t)ide analogue before chemotherapy (245). To date, most studies have used lamivudine (245,246), and a meta-analysis of 21 studies showed a mortality benefit (247). There are data from three RCTs of lamivudine prophylaxis in patients undergoing chemotherapy, involving transarterial chemoembolization for HCC (248) or lymphoma treatment (249,250). However, most HBV treatment provider experts prefer the use of anti-HBV agents with higher antiviral potency and lower risk of resistance (ie, tenofovir or entecavir) with entecavir being preferred in cases with renal disease (251–254). HBV DNA should be monitored while on treatment to exclude noncompliance and virological breakthrough. Pre-emptive therapy is more effective then after reactivation; thus, ideally, treatment is started one month before immmunosuppression onset (250). Therapy should be continued until 12 months after the last dose of the immunomodulatory drug.
In HBsAg-negative patients (ie, occult HBV infection), prophylactic antiviral therapy is not routinely recommended, because the risk of reactivation is considered to be low overall, but all patients should have periodic monitoring of HBV serology. In cases with significant immunosuppression and if HBV DNA levels are unable to be monitored regularly, the safest strategy may be emperical prophylaxis and treat as for a HBsAg-positive patient. If HBV DNA is detectable before treatment, antiviral prophylaxis is recommended. However, if HBV DNA is undetectable, HBV DNA levels should be checked every one to three months, and with any increasing viremia start antiviral prophylaxis.
Many jurisdictions have developed guidelines that restrict the practice of health care providers who perform exposure prone procedures (EPP). According to the Society for Healthcare Epidemiology of America, an EPP is one that involves one or more of the following: digital palpation of a needle tip in a body cavity or the simultaneous presence of a sharp instrument and a health care worker’s finger in a blind or highly confined anatomical site; repair of major traumatic injuries; and manipulation or removal of oral or perioral tissue including tooth structures (255,256). Overall, the risk of HBV transmission from health care provider to patient is low, and most cases reported in the scientific literature occurred before the adoption of or due to lapses in universal precautions (routine practices). Moreover, given universal childhood vaccination for HBV in Canada, fewer patients and health care professionals are at risk of acquiring acute hepatitis B. However, hepatitis B-infected health professionals may choose to take treatment to reduce viral load and thereby preserve their careers. There is no definitive level of HBV DNA below which infection cannot occur, although the lowest viral concentration associated with documented transmission was 4000 copies/mL (approximately 800 IU/mL) (257).
A HBV DNA level of <2000 IU/mL (10,000 copies/mL) was chosen by the European Consensus Group in 2003 (257) and the Society for Healthcare Epidemiology of America in 2010 (256) for the performance of EPPs. In the United Kingdom, if HBV DNA is <200 IU/mL, surgeons can continue to operate. In general, we agree with these recommendations but an undetectable HBV DNA by sensitive kinetic PCR should be the goal. Therefore, any HBV-positive health care provider with high viral load should refrain from performing EPPs, except on patients who are either HBV-infected (HBsAg positive) or HBV immune (anti-HBs positive) unless their infectivity status changes – whether by natural immunity or from antiviral therapy. An HBV-infected physician with HBV DNA <2000 IU/mL (10,000 copies/mL) should be permitted to perform EPP using double gloves and universal precautions with the proviso that their personal physician provides regular (every three months) confirmation that his or her HBV DNA level is below this level.
HDV is a small defective RNA virus that requires HBsAg to complete its lifecycle and propagate infection (258). HDV may be acquired as a coinfection simultaneously with hepatitis B or as a superinfection in a patient who already is a hepatitis B carrier. It is a difficult-to-treat infection that usually causes an aggressive hepatitis and is associated with a higher risk of cirrhosis and HCC than HBV monoinfection. HDV infection is uncommon in North American. Those at highest risk for HDV infection are HBsAg carriers who acquired their infection through injection drug use and immigrants from endemic regions (ie, Mediterranean countries, Eastern Europe and Latin America [5% to 8% of HBsAg-positive carriers]) (259,260). Patients with these risk factors, particularly in the setting of a high ALT with undetectable HBV DNA, should be tested for HDV antibody. If the HDV antibody is positive, active infection should ideally be confirmed with an HDV RNA; treatment considered in those with active infection. The HDV RNA assay is not commercially available, and home-grown assays are not standardized. Patients with active hepatitis D should be treated in expert centres. Unfortunately, the infection is difficult to treat. Lamivudine appears to have no role in the management of HDV and clinical data using the more potent oral anti-HBV agents entecavir and tenofovir are lacking. A recent Cochrane review of six randomized trials using interferon treatment showed that while interferon alpha is effective for suppressing viral replication, it does not eradicate infection (261). In a recent international study conducted in chronic hepatitis D patients from Germany, Turkey and Greece, treatment with PEG IFN alpha-2a for 48 weeks, with or without adefovir, resulted in sustained HDV RNA clearance in approximately one-quarter of patients with HDV infection (262). Although there was no difference in the biochemical and virological response (both HBV DNA and HDV RNA), the combination therapy group demonstrated a marked reduction in serum HBsAg levels, which correlated positively with HDV RNA reduction. Therefore, new studies using combination interferon and newer nucleoside analogues such as tenofovir may lead to better results in these patients. Treatment response should be monitored with HDV RNA testing at month 6 and in those who fail to achieve at least a 3-log drop, therapy should be discontinued. Alternatively, in the absence of HDV RNA monitoring, normalization of the ALT would suggest suppression of virus.
FUNDING: Funding for this meeting was provided through an unrestricted grant from the Canadian Liver Foundation. The Canadian Liver Foundation has received donations from pharmaceutical companies that have products that were discussed at the meeting.
DISCLOSURES: This will serve as a general disclosure for all speakers and the members of the Writing Committee. Many, but not all of the speakers and writers have or have had relationships with the pharmaceutical companies. These relationships include having received research grants, honoraria for speaking engagements or for work on advisory boards related to all of the products discussed in this document.
Dr Coffin has received research support and/or speaker and consultant fees from Gilead, Roche, Bristol Myers Squibb and Merck pharmaceuticals.
Dr. Ma has received research support and consultant fees from Gilead, Merck, Roche and Vertex pharmaceuticals.